Action plan for pharmaceutical companies to accelerate the transition to non-animal science

A new practical resource, developed by Eurogroup for Animals and RSPCA in collaboration with several pharmaceutical companies, outlines key actions that individual companies can take to accelerate the transition towards non-animal science in pharmaceutical development and testing. The pharmaceutical industry has already shown a strong commitment to advancing non-animal approaches, with many companies achieving significant reductions in their use of animals for research and testing purposes. However, transitioning to non-animal science remains a complex and long-term challenge, and some companies may struggle to identify where to start and which actions to prioritize.

The Action Plan developed by Eurogroup for Animals and RSPCA, in collaboration with pharmaceutical companies such as Novo Nordisk, Merck, and Sanofi, provides key actions including identifying opportunities, fostering collaborations, increasing the exchange of knowledge and data, investing in infrastructure and training, and creating funding mechanisms to support these efforts. By implementing and sharing these actions, pharmaceutical companies can play a crucial role in accelerating the transition towards non-animal science in the future.